Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company’s future sales growth as its best-selling eye drug Eylea faces more competition. Regeneron is bracing for a hit to Eylea’s sales by focusing on expanding Dupixent’s label to reach more patients and venturing into the hot new field of immuno-oncology with a potential regulatory approval later this year. Just two days ago, Regeneron and partner Sanofi SA slashed the price on Praluent by more …read more
Source:: Yahoo Finance
